Volume 387, Issue 10037, Pages 2507-2520 (June 2016) Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial Prof Robert M Anthenelli, MD, Prof Neal L Benowitz, MD, Prof Robert West, PhD, Lisa St Aubin, DVM, Thomas McRae, MD, David Lawrence, PhD, John Ascher, MD, Cristina Russ, MD, Alok Krishen, MS, Prof A Eden Evins, MD The Lancet Volume 387, Issue 10037, Pages 2507-2520 (June 2016) DOI: 10.1016/S0140-6736(16)30272-0 Copyright © 2016 Elsevier Ltd Terms and Conditions
Figure 1 Trial profile: non-psychiatric cohort The Lancet 2016 387, 2507-2520DOI: (10.1016/S0140-6736(16)30272-0) Copyright © 2016 Elsevier Ltd Terms and Conditions
Figure 2 Trial profile: psychiatric cohort The Lancet 2016 387, 2507-2520DOI: (10.1016/S0140-6736(16)30272-0) Copyright © 2016 Elsevier Ltd Terms and Conditions
Figure 3 Continuous abstinence rates for weeks 9–12 and 9–24 Analyses based on the all-randomised population. OR=odds ratio. The Lancet 2016 387, 2507-2520DOI: (10.1016/S0140-6736(16)30272-0) Copyright © 2016 Elsevier Ltd Terms and Conditions